Precede Biosciences
Humphrey Gardner is an experienced medical executive currently serving as Consulting CMO at Precede Biosciences since July 2024. Prior to this role, Gardner held the position of Chief Medical Officer at HARBOUR BIOMED from April 2022 to September 2023 and Chief Medical Officer at Silicon Therapeutics from December 2019 to December 2022. Additional experience includes CMO in Residence at Roivant Sciences, Chief of Medical Oncology at Evelo Biosciences, and senior leadership roles at Karyopharm Therapeutics, AstraZeneca, Novartis, and Biogen Idec. Gardner's academic credentials include an MB BChir in Medicine from the University of Cambridge, a Master of Science in Bioinformatics from Brandeis University, and advanced training in Anatomic Pathology from Harvard Medical School.
This person is not in any teams
Precede Biosciences
1 followers
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.